Back to search
FDAFDA · Food and drugs·Recall number D-0033-2026

Cetirizine Hydrochloride Tablets USP 10 mg, 500 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-402-50

Published October 29, 2025 · Recall initiated: September 12, 2025

Summary

FDA records drug Class III recall D-0033-2026, published October 29, 2025 and initiated September 12, 2025. Recalling firm: JB Chemicals and Pharmaceuticals Ltd; Status: Ongoing; Reported quantity: 13,440 bottles; Lot: Lot # PY925014, PY925013, Exp. 1/31/2028. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Tablet/Capsules Imprinted with Wrong ID

What to do

Voluntary: Firm initiated · Letter

Get an email if CETIRIZINE HYDROCHLORIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CETIRIZINE HYDROCHLORIDE
Manufacturer
JB Chemicals and Pharmaceuticals Ltd
Distributor
U.S. Nationwide
Lot
Lot # PY925014, PY925013, Exp. 1/31/2028
Risk classification
Class III
Area (FDA)
drug
Country
India

Related recalls

Questions about this recall

Was Cetirizine Hydrochloride Tablets USP 10 mg, 500 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-402-50 recalled?

Yes. FDA published recall D-0033-2026 on October 29, 2025. Reported hazard: Tablet/Capsules Imprinted with Wrong ID

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CETIRIZINE HYDROCHLORIDE.